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Here, we evaluated a previously established peptide nucleic acid-ﬂuorescence in situ hybridization (PNA-FISH) method as a new
diagnostic test for Helicobacter pylori clarithromycin resistance detection in parafﬁn-embedded gastric biopsy specimens. Both
a retrospective study and a prospective cohort study were conducted to evaluate the speciﬁcity and sensitivity of a PNA-FISH
method to determine H. pylori clarithromycin resistance. In the retrospective study (n 30 patients), full agreement between
PNA-FISH and PCR-sequencing was observed. Compared to the reference method (culture followed by Etest), the speciﬁcity and
sensitivity of PNA-FISH were 90.9% (95% conﬁdence interval [CI], 57.1% to 99.5%) and 84.2% (95% CI, 59.5% to 95.8%), re-
spectively. In the prospective cohort (n 93 patients), 21 cases were positive by culture. For the patients harboring clarithromy-
cin-resistant H. pylori, the method showed sensitivity of 80.0% (95% CI, 29.9% to 98.9%) and speciﬁcity of 93.8% (95% CI,
67.7% to 99.7%). These values likely represent underestimations, as some of the discrepant results corresponded to patients in-
fected by more than one strain. PNA-FISH appears to be a simple, quick, and accurate method for detecting H. pylori clarithro-
mycin resistance in parafﬁn-embedded biopsy specimens. It is also the only one of the methods assessed here that allows direct
and speciﬁc visualization of this microorganism within the biopsy specimens, a characteristic that allowed the observation that
cells of different H. pylori strains can subsist in very close proximity in the stomach.
Helicobacter pylori is a Gram-negative bacterium that colonizesthe human stomach mucosa and plays a major role in several
gastric diseases such as peptic ulcer disease, gastric mucosa-asso-
ciated lymphoid tissue (MALT) lymphoma, and gastric carci-
noma (1–3). Typically, treatment of H. pylori infection necessi-
tates the administration of a proton pump inhibitor with two
antibiotics, clarithromycin and amoxicillin or metronidazole, for
a period of 7 to 14 days, according to the guidelines of the Maas-
tricht Consensus in Europe and theAmericanGastroenterological
Association in the United States (4, 5). The excessive and indis-
criminate use of clarithromycin is leading to an increase of H.
pylori resistance to this antibiotic, reducing the treatment success
(6–9). The prevalence of primary clarithromycin resistance
reaches 30% in southern European countries and in the United
States is around 10% to 15% (7, 9).
Although several resistance mechanisms can occur, clarithro-
mycin resistance in H. pylori is almost always associatedwith point
mutations in the peptidyltransferase region encoded by the V do-
main of the H. pylori 23S rRNA gene (10–12). The three most
prevalent point mutations are the transitions A2142G and
A2143G and the transversion A2142C (7, 10, 13, 14). Other point
mutations in this gene may also be associated with clarithromycin
resistance, but either these are less prevalent or a causal link be-
tween them and resistance has yet to be deﬁnitely proven (15–18).
The agar dilution method is the reference method proposed by
the Clinical and Laboratory Standards Institute (CLSI), formerly
the National Committee for Clinical Laboratory Standards, to be
used for H. pylori antibiotic susceptibility testing (19, 20). Alter-
natively, clinical laboratories use the Etest method as it is consid-
ered less technically demanding (21, 22). However, the Etest and
the agar dilution method are more tedious and time-consuming
to perform than molecular methods such as PCR or ﬂuorescence
in situ hybridization (FISH) (23–25). PCR-based methods have
been used as a suitable alternative (18, 25–27) but can be affected
by DNA contamination or degradation (12, 28). FISH is typically
based on ﬂuorescently labeled DNA probes that hybridize with
speciﬁc rRNA sequences of microorganisms (23, 29). Limitations
of this method include the degradation of the probe by proteases
and nucleases present in the sample, poor permeability of the mi-
crobial cell wall for the probes, and low accessibility of the probe to
the target region of the rRNA due to the ribosomal secondary
structure. To overcome these limitations, peptide nucleic acid
(PNA) probes are being used instead of the typicalDNAmolecules
(28). PNA molecules are synthetic DNA mimics with a neutrally
charged chemical backbone that confers higher afﬁnity for DNA
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or RNA complementary sequences (30, 31). PNA probes are usu-
ally smaller (approximately 13 to 18 bp) than DNA probes (18
bp), increasing their ability to penetrate the bacterial cell wall, and
are more resistant to nucleases and proteases (30).
PNA-FISH methods have been previously developed by our
group for the detection of H. pylori in gastric biopsy specimens
and determination of clarithromycin susceptibility (32). How-
ever, only a preliminary assessment was performed regarding the
sensitivity and speciﬁcity of the methods applied to gastric biopsy
specimens. In the present work, we validated a PNA-FISH assay
for H. pylori and clarithromycin susceptibility determination in
parafﬁn-embedded gastric biopsy specimens, using culture and
Etest as reference methods and a PCR-based method in retrospec-
tive and prospective studies.
MATERIALS AND METHODS
Study settings. Both a retrospective study and a prospective cohort study
were conducted to evaluate the speciﬁcity and sensitivity of a PNA-FISH
method to determine H. pylori clarithromycin resistance (33). PNA-FISH
results were compared to those of other commonly used methods,
namely, in vitro susceptibility testing (Etest) following culture and PCR-
sequencing, to assess resistance status. The threemethodswere performed
in different Portuguese institutions by different laboratory technicians,
who were unaware of the results provided by the other methods. PNA-
FISH was performed at the Centre of Biological Engineering at the Uni-
versity of Minho (CEB), H. pylori culture and Etest were performed at the
Instituto Nacional de Saúde Dr. Ricardo Jorge in Lisbon (INSARJ), and
PCR-sequencing was carried out at the Instituto de Patologia e Imunolo-
gia Molecular da Universidade do Porto (IPATIMUP). This study was
previously approved by the ethics committee of the Portuguese Institute
of Oncology (IPO) in Porto, and informed consent was obtained from all
patients.
Retrospective study. Thirty parafﬁn-embedded gastric biopsy speci-
mens from 24 patients (20 cases with a single biopsy specimen, 2 cases
with 2 biopsy specimens, and 2 cases with 3 biopsy specimens) collected
between 2003 and 2009 at Endoclab (Porto, Portugal) were used. The
selected biopsy specimens were all H. pylori positive and had a known
clarithromycin resistance status determined by Etest. The same biopsy
specimens were then analyzed by PNA-FISH and PCR-sequencing (see
descriptions of methods below).
Prospective study. Ninety-three patients who submitted to an upper
gastrointestinal endoscopywith biopsy collection at IPOduring 2010 par-
ticipated in this study. There was no previous information about H. pylori
resistance for any of these patients. Thirty-ﬁve of them were taking anti-
biotics or proton pump inhibitors during the last month before biopsy
specimen collection. Four biopsy specimens were collected from each
patient. Two (one from the antrum and the other from the corpus) were
used for histopathological examination at IPO, one from the antrum was
used for culture and Etest, and another from the antrum was used for
PNA-FISH and PCR-sequencing.
Culture and clarithromycin susceptibility testing.One antral biopsy
specimen was placed at 4°C in a transport medium (Portagerm pylori;
bioMérieux,Marcy l’Etoile, France).Within less than 24 h, the samplewas
transported to INSARJ, where H. pylori culture and in vitro susceptibility
testing were performed as previously described (34). Brieﬂy, biopsy spec-
imens were ground with a tissue homogenizer (Ultra Turax; Labo Mo-
derne, Paris, France) and inoculated into a selective medium (bioMérieux,
Marcy l’Etoile, France) and a nonselective medium (Biogerm, Maia, Por-
tugal) at 37°C in a microaerobic environment (Anoxomat; MART Micro-
biology BV, Drachten, The Netherlands) for up to 14 days of incubation.
Identiﬁcation of H. pylori was performed according to conventional tests
(assays of colony and Gram stain morphology, catalase, oxidase, and hy-
drolysis of urea).
Susceptibility testing for clarithromycin was performed by the Etest
(bioMérieux, Marcy l’Etoile, France). In brief, a bacterial suspension with
opacity equivalent to the McFarland 3 standard was inoculated by swab-
bing on plates containing Mueller-Hinton agar medium (Becton Dickin-
son, Madrid, Spain) and 10% (vol/vol) horse blood (Probiológica, Belas,
Portugal). Plates were incubated at 37°C under microaerobic conditions
and analyzed after 72 h of incubation. The MIC breakpoint used for cla-
rithromycin was1 g/ml (35).
Handling of parafﬁn-embedded gastric biopsy specimens. Twenty-
four-hour formalin-ﬁxed gastric biopsy specimens were parafﬁn embed-
ded and subsequently analyzed by PCR-sequencing and PNA-FISH. Bi-
opsy specimens were processed overnight with subsequent immersion in
solutions of 4% buffered formaldehyde (Prolabo, VWR, Portugal) twice
for 1 h each time, 80% ethanol (Proclínica, Odivelas, Portugal) for 1 h,
96% ethanol for 1 h, 96% ethanol for 1 h 30 min, 99% ethanol twice for 1
h 30 min each time, 96% ethanol for 1 h 30 min, xylol (Sigma-Aldrich,
Sintra, Portugal) twice for 1 h 30 min each time, and parafﬁn (Thermo
Shandon, United Kingdom) at 60°C twice for 1 h 30 min each time. Sub-
sequently, the material was included in parafﬁn blocks and identiﬁed with
the number of the examination. Cuts of 3-m- and 10-m-thick sections
of parafﬁn-embedded blocks were obtained from each biopsy specimen,
changing the blade after each cut to avoid cross-contamination.
PCR-sequencing.Total DNA was extracted from 10-m-thick cuts of
parafﬁn-embedded biopsy samples after digestionwith proteinaseK for at
least 12 h at 55°C. Proteinase K was inactivated by incubation at 95°C for
10 min. Ten microliters of the lysates was used for PCR of the human
housekeeping gene glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), to monitor the DNA quality, as previously described (36). A
1-l volume of the lysate was also used for PCR ampliﬁcation of the H.
pylori 23S rRNA gene using previously described primers (27). PCR prod-
ucts were sequenced using BigDye Terminator v3.1 cycle sequencing kits
(Applied Biosystems, Foster City, CA) and run in anABI Prism 3130DNA
automated sequencer (Applied Biosystems). The genotype of H. pylori
strains found in patients 1 to 8 of the prospective study (see Table 2) was
also assessed by GenoType HelicoDR (Hain Lifescience, Germany) ac-
cording to the manufacturer’s instructions and a protocol previously de-
scribed (6). The GenoType HelicoDR is a CE-marked kit that was devel-
oped to detect the same pointmutations thatwere assessed in this study by
PNA-FISH (6).
PNA-FISH. Three-micrometer-thick parafﬁn cuts, adhered to mi-
croscopy slides, were deparafﬁnized and rehydrated in xylol and ethanol
based on a previously described protocol (32, 37). Sections were im-
mersed in xylol (Fisher Chemical, Leicestershire, United Kingdom) three
times (the ﬁrst time for 15 min and then twice for 10 min each time),
absolute ethanol (Panreac, Barcelona, Spain) (twice for 7 min 30 s each
time), and decreasing concentrations of ethanol (95% twice for 7 min 30
s each time; 80% for 10 min; 70% for 10 min; and 50% twice for 15 min
each time). Finally, sections were immersed in 1% (vol/vol) Triton X-100
(Sigma-Aldrich, Sintra, Portugal) solution for 20 min at 63°C. Histologi-
cal slides were then allowed to air dry.
The probes previously developed by our group to assess H. pylori cla-
rithromycin resistance were shortened from 15 bp to 13 bp (for Hp1,
5=-GTC TCT CCG TCT T-3=; for Hp2, 5=-GTC TTC CCG TCT T-3=; for
Hp3, 5=-GTC TTG CCG TCT T-3=; and for Hpwt, 5=-GGT CTT TCC
GTC T-3=) in order to carry out hybridization assays at a lower tempera-
ture but with the same speciﬁcity performance (data not shown). Probes
detectingmutations that conferred clarithromycin resistancewere labeled
with Alexa Fluor 488 (emission in the green wavelength), whereas the
probe targeting susceptible strains was labeled with Alexa Fluor 594
(emission in the red wavelength). Approximately 20 l of hybridization
solution was added to the histological slides, which were then covered
with coverslips and incubated for 1 h at 63°C. The hybridization solution
contained a 200 nM concentration of the probe mixture, 10% (wt/vol)
dextran sulfate, 10 mM NaCl, 30% (vol/vol) formamide, 0.1% (wt/vol)
sodium pyrophosphate, 0.2% (wt/vol) polyvinylpyrrolidone, 0.2% (wt/
vol) Ficoll, 5 mM disodium EDTA, 0.1% (vol/vol) Triton X-100, and 50
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mM Tris-HCl (all from Sigma-Aldrich, Sintra, Portugal, except the diso-
dium EDTA, which was from Pronalab, Lisbon, Portugal). Subsequently,
the slides were transferred to a Coplin jar containing prewarmed (63°C)
washing solution that consisted of 5 mM Tris base, 15 mM NaCl, and 1%
(vol/vol) Triton X-100 (all from Sigma-Aldrich, Sintra, Portugal), where
the coverslips were carefully removed. The washing step was carried out
for 30 min at 63°C. The slides were allowed to air dry and mounted with
one drop of mounting oil and covered with a coverslip before microscopy
observation. The completion of the whole procedure took approximately
3 h.
Microscopic visualization. Histological slides of the PNA-FISH pro-
cedure were observed using an epiﬂuorescence microscope (BX51 Olym-
pus, Hamburg, Germany) equipped with a charge-coupled-device (CCD)
camera (DP71; Olympus) with ﬁlters adapted to the Alexa Fluor 488
(bandpass [BP] 470- to 490-nm exciter ﬁlter, farb teiler [FT] 500-nm
splitter, longpass [LP] 516-nm ﬁlter) and 594 (BP 530- to 550-nm exciter
ﬁlter, FT 570-nm splitter, LP 591-nm ﬁlter) signaling molecules attached
to the probes. The ﬁlters that were not sensitive to the reporter molecules
were used as negative controls. Visualization of samples was carried out
within less than 48 h after the experimental PNA-FISH procedure.
Validity indexes. Statistical validity parameters such as sensitivity,
speciﬁcity, likelihood ratios, and respective 95% conﬁdence intervals (CI)
were determined as previously described (38, 39), using the VassarStats:
Website for Statistical Computation (http://vassarstats.net).
RESULTS
PNA-FISH optimization. The four PNA probes were ﬁrst tested
separately to ensure that the shortening of the sequences would
not affect the individual performance of each probe. Because the
purpose of this study was not to discriminate individually each
point mutation associated with clarithromycin resistance but
rather to discriminate between susceptible and resistant H. pylori
strains, a mixture of the four PNA probes was used instead for the
rest of the work. Both the individual probes and their mixture
were highly sensitive and speciﬁc to detect H. pylori of a known
status in gastric biopsy specimens (Fig. 1A toD). Furthermore, the
presence of mixed infections with cells of susceptible and resistant
H. pylori strains located less than 5 m apart within the same
biopsy specimen was also detectable by the PNA probes (Fig. 1E
and F).
Retrospective study.Of the 30 histological samples, 26 showed
total agreement between the Etest, PNA-FISH, and PCR-sequenc-
ing (86.7% concordance; 95% CI, 68.4% to 95.6%). Of these, 10
samples were considered to have susceptible H. pylori strains and
16 to have resistant strains (see Table S1 in the supplemental ma-
terial). Overall, the PNA-FISH method was in full agreement with
PCR-sequencing (Table 1; see also Tables S1 and S3 in the supple-
mental material), but because the culture and Etest are considered
to be the reference methods, PNA-FISH showed speciﬁcity and
sensitivity of 90.9% (95% CI, 57.1% to 99.5%) and 84.2% (95%
CI, 59.5% to 95.8%), respectively. Three samples presented a sus-
ceptible genotype but a resistant phenotype, whereas in one sam-
ple a resistant genotype and a susceptible phenotype were ob-
served. In the particular case of patient 6, in two distinct biopsy
specimens, two different H. pylori strains (one resistant and the
other susceptible) were detected (see Table S1 in the supplemental
material).
Prospective study. Of a total of 93 patients, the biopsy speci-
mens of 21 were positive for H. pylori by culture and hence were
included for the sensitivity and speciﬁcity determinations (Table
1; see also Tables S2 and S3 in the supplemental material). The
biopsy specimens of 5 patients presented a resistant phenotype,
and those of the other 16 presented a susceptible phenotype. Be-
sides PNA-FISH, other molecular methods, namely, GenoType
HelicoDR for patients 1 to 8 and PCR-sequencing for patients 9 to
21, were also tested. The latter two methods were used inter-
changeably because, as indicated by Cambau et al. (6), the concor-
dance between GenoType HelicoDR results and those of genotyp-
ing is 99.5%.
Regarding the H. pylori strains with a resistant phenotype, one
of them (corresponding to patient 19) could not be conﬁrmed by
PNA-FISH, since no bacterial cells could be visualized in the bi-
opsy sample used to perform this method. For patients 18 and 21,
the PNA-FISH method detected both genotypes (resistant and
susceptible). When this occurred, the patient was considered to be
resistant to clarithromycin, as it was considered that the presence
of both genotypes would lead the clinical physician to use a ther-
apy not involving clarithromycin. Therefore, PNA-FISH showed a
sensitivity of 80.0% (95% CI, 29.9% to 98.9%) and a speciﬁcity of
93.8% (95% CI, 67.7% to 99.7%) for the detection of resistant
strains. The positive-likelihood ratio was 12.9, indicating a strong
FIG 1 Detection of H. pylori strains in gastric biopsy histological slides by
PNA-FISH. (A) Visualization of a resistant strain in the green channel. (B)
Visualization of the same microscopic ﬁeld in the red channel, where no H.
pylori-sensitive strains are present. (C) Visualization of a susceptible strain in
the red channel. (D) Visualization of the microscopic ﬁeld presented in panel
C in the green channel. The very faint cells that are picked up in the green
channel are the result of bleed through, but the signal intensity can be easily
differentiated from that of a true positive signal. (E and F) Presence of a mixed
infection within the same biopsy specimen. (E) H. pylori cells that contain the
pointmutations associatedwith clarithromycin resistance and that can be seen
only in the green channel (solid arrows). (F) H. pylori cells in which no point
mutations are present (wild type) and that can be seen only in the red channel
(dashed arrows). As can be observed in panels E and F, cells of different H.
pylori strains can subsist in very close proximity in the stomach (in locations
less than 5 m apart). They also appear interspersed in the biopsy specimen
and are not segregated according to species. Images were obtained with equal
exposure times. (Original magniﬁcation,600).
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association between a PNA-FISH-positive result and the proba-
bility of the sample having a resistant H. pylori strain (38, 39)
(Table 2). Regarding the biopsy specimens harboring H. pylori
with a susceptible phenotype, PNA-FISH detected both suscepti-
ble and resistant genotypes for patient 13 (Fig. 1E and F), whereas
the other two methods detected the only clarithromycin-suscep-
tible H. pylori strain.
Among the 72 patients that were H. pylori negative by culture,
in 12 cases the housekeeping geneGAPDHcould not be ampliﬁed,
suggesting either that the DNA was degraded or that there were
PCR inhibitors, and these cases were not further assessed by PCR-
sequencing. In the remaining 60 cases, 36 (60%) were also nega-
tive by both PNA-FISH and PCR-sequencing (Fig. 2). Fourteen
(23%) cases were positive by both PNA-FISH and PCR-sequenc-
ing (13 susceptible and 1 resistant). In 10 patients, discrepant re-
sults were obtained with the molecular methods: in 8 (14%) bi-
opsy samples, H. pylori was detected by PNA-FISH but no positive
result was obtained by PCR, whereas 2 (3%) patients tested posi-
tive by PCR but were negative by PNA-FISH. In these cases, the
use of nonspeciﬁc dyes in the biopsy specimens indicated that no
bacterial cells were present in the tissue sections used for PNA-
FISH.
DISCUSSION
New methods capable of detecting H. pylori clarithromycin sus-
ceptibility proﬁle in a rapid and simple way became an emerging
concern due to increased therapy failure of H. pylori. Here, we
evaluated a new diagnostic method, based on PNA-FISH, that is
able to provide results in a very short period of time, meaning that
a diagnosis can be obtained in less than 24 h. For that, assays
comparing the PNA-FISH technique with the standard methods
(culture and Etest) and other molecular methods (PCR-sequenc-
ing, GenoType HelicoDR) were performed in retrospective and
prospective studies.
Regarding the retrospective study, the few discrepancies be-
tween the molecular methods and the Etest in the results obtained
may have two possible explanations. The ﬁrst one is related to the
existence of mechanisms of resistance apart from those associated
with the three point mutations assessed in this study (15, 40, 41).
In fact, the 86.7% concordance obtained between PNA-FISH and
the Etest is in agreement with what has been observed in other
studies, where the three point mutations assessed here were pres-
ent in 84% to 90% of clarithromycin-resistant H. pylori strains (7,
14). The other explanation is the possibility of the presence of two
or more H. pylori strains in the same patient (i.e., a mixed infec-
tion). Recent studies seem to support the view that mixed infec-
tions in the stomach environment are much more common than
previously thought (13, 22, 42–44), an observation that is also
supported by this study (see below). The fact that the biopsy spec-
imen used for culture was not the same one used for the molecular
methods only increases the chances that different strains were
evaluated by different methods.
In one case, two genotypes were identiﬁed in two different
biopsy specimens by both PNA-FISH and PCR-sequencing,
whereas the culture method identiﬁed only the resistant strain.
Because the culture used a different biopsy specimen, it is possible
that only one of the strains was present in there. An alternative
would be the overgrowth of the resistant strain in the culture plate,
inhibiting the growth and recovery of the susceptible strain. In any
case, the fact that the two molecular methods were in agreement
strongly points to the presence of amixed infection in that patient.
Furthermore, that patient samplewould be considered resistant to
clarithromycin by all three methods.
In general, the results obtained for the prospective study were
not very different from those obtained for the retrospective study,
and many of the arguments used above to explain discrepant re-
sults are also applicable to the prospective study. One of the ob-
servations that occurred only in the prospective study was the
TABLE 1 Summary of the results obtained for the clarithromycin-
resistant samples in the retrospective and prospective studies
Method and resulta
No. of samples with
indicated result
Etest
positive
Etest
negative
Retrospective study
PNA-FISH-positive result 16 1
PNA-FISH-negative result 3 10
Positive result by other molecular method 16 1
Negative result by other molecular method 3 10
Prospective study
PNA-FISH-positive result 4 1
PNA-FISH-negative result 1 15
Positive result by other molecular method 4 0
Negative result by other molecular method 1 16
a Other molecular method, GenoType HelicoDR or PCR-sequencing.
TABLE 2 Validation indexes obtained for the prospective study
comparing the PNA-FISH- and PCR-based methods to the in vitro
susceptibility Etest for the resistance results
Parameter PNA-FISH value(s)
Value(s) determined by other
molecular methoda
Sensitivity 80% (95% CI, 29.9%–98.9%) 80% (95% CI, 29.9%–98.9%)
Speciﬁcity 93.8% (95% CI, 67.7%–96.7%) 100% (95% CI, 75.9%–100%)
Likelihood ratio
positive
12.9 Inﬁnite
Likelihood ratio
negative
0.21 0.2
a Other molecular method, GenoType HelicoDR or PCR-Sequencing.
FIG 2 Correspondence between the molecular results (PCR-sequencing and
PNA-FISH) for biopsy specimens that were negative by culture in the prospec-
tive study. The ﬁgure key presents the percentage of cases associated with each
correspondence, as well as the number of cases.
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simultaneous presence of resistant and sensitive strains in a single
biopsy specimen, as assessed by PNA-FISH. This observation
highlights and reinforces the idea that mixed infections are more
common than previously considered. In this speciﬁc case, differ-
ent H. pylori strains appear interspersed in the same biopsy spec-
imen and do not seem to occupy speciﬁc niches. In fact, cells
belonging to different H. pylori strains are found less than 5 m
apart but not in direct contact. PNA-FISH is the only method that
is able to provide this type of information, and in the future use of
the method might be invaluable to bring further information on
the distribution and localization of different H. pylori strains.
Overall, the validity index values for resistance obtained for the
H. pylori-positive patients of the prospective study support the
idea that the PNA-FISH and PCR-based methods are accurate
means of detecting and delineating clarithromycin-resistance sta-
tus (Table 2). However, PCR-based methods require DNA isola-
tion and ampliﬁcation,which implies that thesemethods aremore
technically demanding and take longer to be accomplished (12).
Interestingly, for PNA-FISH a variation of predictive values is ex-
pected to occur in accordance with variable rates of resistance to
clarithromycin (Table 3). In spite of the likely underestimation of
the speciﬁcity and sensitivity of PNA-FISH, due to the presence of
two or more strains in some patients, high positive predictive val-
ues are expected for a prevalence level ranging between 20% and
30%, which are typical resistance rates in the more developed
countries (9, 45, 46).
Patient specimens that were H. pylori negative by culture were
positive by one or both molecular methods. It is well known that
H. pylori is a fastidious bacterium that needs to be handled very
carefully in order to be recovered in culture medium (6, 12, 47).
To ensure the best possible conditions to promote H. pylori
growth, all biopsy samples were processed in less than 24 h and
were transported in a speciﬁc medium under refrigerated condi-
tions. Nonetheless, it appears likely that H. pylori was present in
some samples but remained uncultured, at least for those cases
where the molecular methods were in agreement (n  14). This
might, for instance, be related to the amount of viable H. pylori
present in the samples (12, 42). Another possible explanation is
the uptake of antimicrobials and proton pump inhibitors by pa-
tients shortly before the endoscopy, a condition that would cause
the microorganism to become unculturable (48). Here, 9 of the
patient samples that were H. pylori negative by culture and posi-
tive by at least one molecular method were in this situation.
For the cases where discrepancies between molecular methods
occurred, 8 samples were H. pylori positive by PNA-FISH but
negative by PCR. However, 5 of these patients were infected with
very low concentrations of H. pylori (only a few bacterial cells per
biopsy sample were detected by PNA-FISH). This indicates that
the limit of detection of PCR might be higher than that of PNA-
FISH. Another possible explanation is the occurrence of false pos-
itives in the results determined by the PNA-FISH method (32). In
fact, the probe targeting susceptible strains is fully complementary
for a signiﬁcant number of species belonging to the Proteobacteria
group and as such is able to detect these bacterial species. How-
ever, when H. pylori is absent, the majority of the stomach micro-
biome is constituted by Gram-positive bacteria (43); as such, the
possibility of false positives occurring is quite low. Another possi-
ble explanation is the presence of H. pylori only in the tissue sec-
tion that was used for PNA-FISH and not in that used for PCR.
The presence of false PCR positives or the heterogeneous distri-
bution of H. pylori strains in the biopsy samplesmight also serve to
explain the presence of two patient samples that tested positive by
PCR but negative by PNA-FISH.
Conclusions. It is well established that clarithromycin resis-
tance reduces the eradication rates of H. pylori gastric infections,
since this antibiotic is one of the drugs most widely used in treat-
ment regimens. Until now, susceptibility tests have mostly been
based on fastidious and time-consuming culture methods. The
requirements for more prompt and accurate methods led us to
develop a PNA-FISH method to detect the three most prevalent
point mutations associated with clarithromycin resistance. PNA-
FISH proved to be a quick technique that can detect with high
accuracy H. pylori strains and discriminate with high speciﬁcity
both susceptible and resistant genotypes on gastric biopsy speci-
mens simultaneously with histology tests. The regular application
of this technique can lead in the future to a more rational antimi-
crobial therapy use and hence improve the patient’s chances of a
more effective H. pylori eradication.
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